Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Login Sign up free
Home Stock ScreenerScreener ETF ScreenerETF Maps Charts News Groups Insider Futures Forex Crypto Watchlist Portfolio Calendar
Pricing

WVE

Wave Life Sciences Inc

Last Close
3.37
Nov 06 • 3:59 PM ET Dollar change+0.14 Percentage change(4.50%)
Aftermarket Close
3.43
Aftermarket • 5:40 PM ET Dollar change+0.07 Percentage change(1.93%)
Overview Compare Short Interest Financials Options Filings Dilution
Healthcare Biotechnology USA Small NASD
Peers: IONS BEAM ARWR DYN ALNY SRPT SLN TRDA ADRX NTLA
 | Held by: IWM VXF XPH IWN IBB VTWO SCHA DFAS IHE FESM
Scroll to Statements
Index
RUT
Market Cap
663.68M
Enterprise Value
276.20M
Income
-210.53M
Sales
70.92M
Book/sh
2.04
Cash/sh
2.18
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
317
IPO
Nov 11, 2015
P/E
-
Forward P/E
-
PEG
-
P/S
9.36
P/B
1.65
P/C
1.54
P/FCF
-
EV/EBITDA
-
EV/Sales
3.89
Quick Ratio
8.38
Current Ratio
8.38
Debt/Eq
0.11
LT Debt/Eq
0.10
Option/Short
Yes / Yes
EPS (ttm)
-1.07
EPS next Y
-1.30
EPS next Q
-0.32
EPS this Y
9.12%
EPS next Y
-17.78%
EPS next 5Y
-1.34%
EPS past 3/5Y
16.10% 20.52%
Sales past 3/5Y
127.08% 16.31%
EPS Y/Y TTM
-45.17%
Sales Y/Y TTM
-35.07%
EPS Q/Q
5.55%
Sales Q/Q
72.95%
Earnings
Oct 27 BMO
EPS/Sales Surpr.
8.81% 191.60%
Insider Own
16.18%
Insider Trans
-0.08%
Inst Own
83.55%
Inst Trans
0.65%
ROA
-56.19%
ROE
-78.80%
ROIC
-47.76%
Gross Margin
86.99%
Oper. Margin
-320.94%
Profit Margin
-296.86%
SMA20
0.23%
SMA50
-13.50%
SMA200
-53.03%
Trades
Shs Outstand
197.21M
Shs Float
165.32M
Short Float
12.80%
Short Ratio
6.31
Short Interest
21.17M
52W High
21.73 -84.51%
52W Low
3.04 10.69%
Volatility
7.80% 6.29%
ATR (14)
0.23
RSI (14)
43.47
Beta
-1.37
Rel Volume
0.66
Avg Volume
3.35M
Volume
2,205,262
Perf Week
-6.27%
Perf Month
-3.03%
Perf Quarter
-44.56%
Perf Half Y
-53.13%
Perf YTD
-80.21%
Perf Year
-57.30%
Perf 3Y
-38.48%
Perf 5Y
-28.40%
Perf 10Y
-90.12%
Recom
1.14
Target Price
18.54
Prev Close
3.22
Price
3.37
Change %
4.50%
Consensus
Strong Buy
Avg. Price Target
$18.54
Implied Upside
+451.0%
Analysts16incl. previous ratings
Rating Distribution15 Buy · 1 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Oct 16, 2026Initiated
WWilliam Blair
Outperform
Oct 15, 2026Initiated
UBS logoUUBS
Buy$11+226.9%
Oct 01, 2026Initiated
LLadenburg Thalmann
Buy$10+197.2%
Sep 23, 2026Resumed
JPM logoJJP Morgan
Neutral
Apr 29, 2026Resumed
TFC logoTTruist
Buy$15+345.8%
Feb 05, 2026Initiated
BAC logoBBofA Securities
Buy$38+1,029.3%
Dec 12, 2025Reiterated
WWedbush
Outperform$20 → $33+880.7%
Dec 09, 2025Upgrade
RY logoRRBC Capital Mkts
Sector Perform → Outperform$27+702.4%
Oct 20, 2025Initiated
WFC logoWWells Fargo
Overweight$18+434.9%
Aug 04, 2025Initiated
CCanaccord Genuity
Buy$19+464.6%
Show Previous News
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Wagner Heidi LDirectorAug 11 '26Option Exercise5.977,00041,79051,930Aug 13 09:00 PM
Wagner Heidi LDirectorAug 11 '26Sale6.017,00042,07044,930Aug 13 09:00 PM
Rawcliffe AdrianDirectorAug 12 '26Sale5.2912,70067,1830Aug 13 09:00 PM
TAKANASHI KENDirectorAug 11 '26Sale6.013,86423,22320,079Aug 13 09:00 PM
Tan Aik NaDirectorAug 11 '26Sale6.014322,59624,968Aug 13 09:00 PM
ADRIAN G RAWCLIFFEDirectorAug 12 '26Proposed Sale5.0412,70064,072Aug 12 04:32 PM
HEIDI L WAGNER DirectorAug 11 '26Proposed Sale6.077,00042,490Aug 11 04:30 PM
RA CAPITAL MANAGEMENT, L.P.DirectorMar 26 '26Buy6.085,305,78232,265,43123,508,791Mar 30 08:30 PM
RA CAPITAL MANAGEMENT, L.P.DirectorMar 27 '26Buy6.432,495,62316,046,85626,004,414Mar 30 08:30 PM
RA CAPITAL MANAGEMENT, L.P.DirectorMar 30 '26Buy6.50971,0916,312,09226,975,505Mar 30 08:30 PM
Francis ChrisSee RemarksFeb 26 '26Option Exercise4.2833,194141,92079,767Feb 27 09:00 PM
Francis ChrisSee RemarksFeb 26 '26Sale15.0533,194499,59361,867Feb 27 09:00 PM
Moran KyleChief Financial OfficerFeb 09 '26Sale13.453,58848,259134,385Feb 11 09:03 PM
BOLNO PAULPresident and CEOFeb 09 '26Sale13.4510,480140,956275,520Feb 11 09:02 PM
Francis ChrisSee RemarksFeb 09 '26Sale13.451,88325,32661,867Feb 11 09:01 PM
Vargeese ChandraSee RemarksFeb 09 '26Sale13.453,22843,417408,246Feb 11 09:00 PM
KYLE MORANOfficerFeb 09 '26Proposed Sale13.453,56447,936Feb 09 09:30 PM
Chris FrancisOfficerFeb 09 '26Proposed Sale13.451,87025,152Feb 09 09:29 PM
PAUL BOLNOOfficerFeb 09 '26Proposed Sale13.4510,411140,028Feb 09 09:27 PM
Francis ChrisSee RemarksJan 02 '26Option Exercise3.149,37529,43834,375Jan 06 09:30 PM
Francis ChrisSee RemarksJan 02 '26Sale16.039,375150,26025,000Jan 06 09:30 PM
GSK plc10% OwnerDec 11 '25Buy19.001,470,00027,930,00018,245,691Dec 15 04:32 PM
Rawcliffe AdrianDirectorDec 08 '25Option Exercise5.9742,000250,74054,700Dec 10 09:45 PM
Rawcliffe AdrianDirectorDec 08 '25Sale15.0042,000630,00012,700Dec 10 09:45 PM
Wagner Heidi LDirectorDec 08 '25Option Exercise5.9714,00083,58051,930Dec 10 09:45 PM
Wagner Heidi LDirectorDec 08 '25Sale13.5014,000189,00044,930Dec 10 09:45 PM
HENRY CHRISTIAN ODirectorDec 08 '25Option Exercise5.0787,000440,79054,700Dec 10 09:45 PM
HENRY CHRISTIAN ODirectorDec 08 '25Sale14.6593,4451,369,32412,700Dec 10 09:45 PM
Tan Aik NaDirectorDec 08 '25Option Exercise4.85119,230578,27070,400Dec 10 09:45 PM
Tan Aik NaDirectorDec 08 '25Sale13.58134,2181,823,15825,400Dec 10 09:45 PM
Verdine Gregory L.DirectorDec 08 '25Sale13.4720,000269,461275,217Dec 10 09:45 PM
Francis ChrisSee RemarksDec 08 '25Option Exercise4.78441,0312,107,183147,349Dec 10 09:45 PM
Francis ChrisSee RemarksDec 08 '25Sale14.57441,0316,427,08525,000Dec 10 09:45 PM
Moran KyleChief Financial OfficerDec 09 '25Option Exercise9.5186,000818,120139,218Dec 10 09:45 PM
Moran KyleChief Financial OfficerDec 08 '25Option Exercise3.43210,000721,300189,218Dec 10 09:45 PM
Moran KyleChief Financial OfficerDec 08 '25Sale14.77210,0003,102,00089,218Dec 10 09:45 PM
Moran KyleChief Financial OfficerDec 09 '25Sale20.0350,0361,001,97989,218Dec 10 09:45 PM
CORRIGAN MARKDirectorDec 08 '25Sale13.4816,115217,29728,815Dec 10 09:45 PM
KYLE MORANOfficerDec 09 '25Proposed Sale18.5286,0001,592,720Dec 09 04:24 PM
Henry Family TrustAffiliateDec 08 '25Proposed Sale18.5293,4451,730,601Dec 08 07:08 PM
HEIDI L WAGNERDirectorDec 08 '25Proposed Sale7.4914,000104,860Dec 08 04:39 PM
KYLE MORANOfficerDec 08 '25Proposed Sale7.49210,0001,572,900Dec 08 04:37 PM
CHRISTOPHER FRANCISOfficerDec 08 '25Proposed Sale7.49483,6023,622,179Dec 08 04:36 PM
GREGORY VERDINEDirectorDec 08 '25Proposed Sale7.4920,000149,800Dec 08 04:35 PM
ADRIAN RAWCLIFFEDirectorDec 08 '25Proposed Sale7.4942,000314,580Dec 08 04:34 PM
MARK CORRIGANDirectorDec 08 '25Proposed Sale7.4916,115120,701Dec 08 04:34 PM
AIK NA TANDirectorDec 08 '25Proposed Sale13.58134,2181,823,158Dec 08 04:29 PM
Rawcliffe AdrianDirectorNov 13 '25Sale6.7916,115109,42112,700Nov 14 09:00 PM
RA CAPITAL MANAGEMENT, L.P.DirectorNov 13 '25Buy6.691,0006,68818,203,009Nov 14 06:14 PM
ADRIAN RAWCLIFFEDirectorNov 13 '25Proposed Sale6.9616,115112,080Nov 13 04:25 PM
Wave Life Sciences, Inc. is a clinical-stage biotechnology company, which focuses on developing its proprietary RNA medicines platform and PRISM. It develops and commercializes a pipeline of RNA medicines across a variety of therapeutic areas. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Cambridge, MA.
M.D.Dr. Paul B. Bolno M.B.A.
Founder & DirectorDr. Gregory L. Verdine Ph.D.
CFO & Principal Accounting OfficerMr. Kyle B. Moran CFA
Chief Technology OfficerDr. Chandra Vargeese Ph.D.
Ph.D.Dr. Erik Ingelsson M.D.
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Affiliate • Advertise • APIs • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)